FREQUENTLY ASKED QUESTIONS

Similar documents
FREQUENTLY ASKED QUESTIONS

FREQUENTLY ASKED QUESTIONS

KEY TO INNOVATION AT VASCUTEK JAPAN MATTERS FEBRUARY 7TH 2014

From the Peripheral Vascular Surgery Society

CAUTION: U.S. Federal law restricts this device to sale by or on the order of a licensed physician.

CapSure Permanent Fixation System

Affinity NT. Clearly the Choice for Consistent Performance. and Reliable Results

4/25/2009. Other 8% Thrombosis? Stenosis 8% 74% Infection 10%

Advancing minimally invasive. therapeutics through novel device. development. Minima y Invasive New Technologies T H E L E O N A M. A N D H A R R Y B.

Bioengineered AV Grafts: They Are Finally Happening! Synthetic Vascular Dialysis Grafts. Vascular Grafts and Failure. Disclosure Information

Proven reliability. P e r f o r m a n c e t h r o u g h e x p e r i e n c e

Session 1 Topics. Vascular Phase of Hemostasis. Coagulation Pathway. Action of Unfractionated Heparin. Laboratory Monitoring of Anticoagulant Therapy

University Hospital. Parkland Hospital

ALLODERM SELECT ALLODERM SELECT RESTORE

TRELLIS COLLAGEN RIBBON

Comfort your patient deserves. Strength you demand.

BAXTER UNVEILS DESIGN ENHANCEMENTS TO FLOSEAL AND TISSEEL HEMOSTATIC AGENTS AT AORN MEETING

Platelet Concentrate in Total Knees BIOLOGICS. This brochure is for International use only. It is not for distribution in the United States.

Perioperative management of patients on warfarin requiring elective surgery Dr K Boyd, Mrs S Doyle

Section 8. To introduce the basic theory and principles of collecting blood for Intraoperative Cell Salvage (ICS)

Repliform. Tissue Regeneration Matrix. Instructions for Use. Distributed by:

Processed from Donated Human Tissue by LifeCell Corporation for KCI USA, Inc.

Artist Proof: Clotalyst. Autologous Serum Collection System

A preliminary study of prosthesis damage by laser energy. James M. Seeger, M.D., George S. Abela, M.D.,* and Nina Klingman, B.S., Gainesville, Fla.

Policies Concerning Survival Surgery of Mice

PREVELEAK Surgical sealant

Me- of Monitoring Heparin Therapy for

DuraGen Secure. Dural Regeneration Matrix

Endovascular Device Testing A Survey of Requirements for Product Validation

Teleflex Incorporated (NYSE: TFX) Investor Presentation

Palindrome Precision Chronic Dialysis Catheter Family

ISO Cardiovascular implants Endovascular devices Part 2: Vascular stents Part 2: Vascular stent

ANTICOAGULANT THERAPY ANTICOAGULANT THERAPY REVISITED 2005

If not heparin for bypass then what? Dr Tony Moriarty Consultant Cardiac Anaesthetist Birmingham United Kingdom

BRIC Surgical Sutures Market Outlook to 2020

YOUR PARTNER. In The Global Life Sciences Market. Value Plastics Fluid Management Components Biomaterial Delivery Devices Avalon Catheter Solutions

Fully Comprehensive Premium Range

BIP Central Venous Catheter

The Incidence of Recognized Heparin- Induced Thrombocytopenia in a Large, Tertiary Care Teaching Hospital*

China-EU Competition Week: Abbott's Acquisition of St. Jude Medical

Surgical Adhesives in Facial Plastic Surgery

STANDARD OPERATING PROCEDURES DIVISION OF COMPARATIVE MEDICINE UNIVERSITY OF SOUTH FLORIDA

S.M.A.R.T. Our inspiration came right from the source. Feeling is believing. S.M.A.R.T. Flex Vascular Stent System. LinkedIn page

Physician Orders - Adult

Policy 19 Fluid Administration and Collection in Rodents Version 1.0 Approval Date: 12/12/12

JOIN THE ARTAS GENERATION. A robotic revolution in speed, precision and accuracy.

Innovations. For Life. EXAFLOW EXTERNAL CSF DRAINAGE PRODUCT CATALOGUE

Clinical Policy Guidelines. Management of patients on antithrombotic agents undergoing colonoscopy procedure following positive FOB test.

DIRECTIONS FOR USE. NATRELLE 133 Plus Tissue Expanders. MAGNA-FINDER Xact. Directions for Use. with Magna-Site. Injection Sites

Harvesting a New Standard of Care

Enoxaparin sodium 150mg (equivalent to 15,000 IU anti-xa. activity) in 0.2ml water for injections. activity) in 0.4ml water for injections

Modular branched endograft system for aortic aneurysm repair: evaluation in a human cadaver circulation model

MIIG INJECTABLE Graft The following languages are included in this packet:

Lovenox weight calculator

RapidPort EZ Port Applier DIRECTIONS FOR USE (DFU)

Bevyxxa (betrixaban) NEW PRODUCT SLIDESHOW

Heparin Induced Thrombocytopenia. Heparin Induced Thrombocytopenia. Heparin Induced Thrombocytopenia. Temporal Aspects.

ORGANISATION AFRICAINE DE LA PROPRIETE INTELLECTUELLE

Scottish Medicines Consortium

intervention embosphere embogold quadrasphere bearing nspva

ADVANCING THE ART OF SINGLE-STAGE REPAIR

BUILT TO CONCENTRATE. Magellan is an autologous concentration system that delivers concentrated platelets and cells at the point of care.

The Ventrio ST Hernia Patch Featuring Sepra Technology. Efficient:

SINGLE ENTRY TUNNELER [SET] FOR HEMODIALYSIS GRAFT PROCEDURES. Authors should be contacted at:

EDUCATIONAL COMMENTARY D-DIMER UPDATE

Continuous Infusion Toxicity Studies in Rats; General Considerations

Workflow optimization in the hybrid OR. Arjan Hoksbergen, Vascular Surgeon Rutger Lely, Interventional Radiologist

PHYSICIAN OFFICE BILLING INFORMATION SHEET FOR IMLYGIC (talimogene laherparepvec)

Insertion of Skin Tunnelled Central Venous Catheter (STC)

Aortic Graft Infection- Contemporary Management of a Resurgent Problem

Bioreactors in tissue engineering

We are IntechOpen, the first native scientific publisher of Open Access books. International authors and editors. Our authors are among the TOP 1%

What makes the technology unique?

Get a Closer Look. Continuing Support

A PROGRESSIVE LEGACY OF PRECISION PERFORMANCE

Applications in Cardiology 3/30/2006 1

Section A Definitions

Prosthetic Vascular Graft Infection

MaineGeneral Medical Center Competency Based Orientation Tool RN Staff Care of the Patient Receiving Intraperitoneal Chemotherapy

A Coordinated Registry Network Based on the Vascular Quality Initiative: VISION. Vascular Implant Surveillance & Interventional Outcomes Network

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)

Learning Objectives include:

Synthetic, Cryograft, or Xenograft: Which Bypass Graft Can Best. Save YOUR Life?

Initial Dose 10,000 units Every 4 to 6 hours 5,000 to 10,000 units. Intermittent IV injection

MITRAL VALVE REPAIR BACKGROUND

LINC James F. McKinsey, M.D.

Protect the Neck. Lieven Maene, MD. Marc Bosiers Koen Deloose Joren Callaert. Patrick Peeters Jürgen Verbist. Lieven Maene Roel Beelen.

DIRECTIONS FOR USE. NATRELLE 133 Tissue Expanders. MAGNA-FINDER Xact. Directions for Use. with Magna-Site. Injection Sites

HEMOSTASIS IN SURGERY

ANALYSIS OF EXPLANTED SILICONE/SILICA COMPOSITE BREAST IMPLANTS

Perspective on initial Limflow experience in the US. Peter A. Schneider, MD Kaiser Foundation Hospital Honolulu, Hawaii

Transcription:

FREQUENTLY ASKED QUESTIONS

Table of Contents GORE ACUSEAL Vascular Graft Properties What is the GORE ACUSEAL Vascular Graft?...2 What is unique about the GORE ACUSEAL Vascular Graft?...3 What are the benefits of the GORE ACUSEAL Vascular Graft?...3 Are the microstructures of GORE-TEX Vascular Grafts and GORE ACUSEAL Vascular Grafts similar?...3 CBAS Surface and Heparin Who is Carmeda AB?...4 Does Carmeda AB have a history of working with heparin technology?...4 What kind of heparin is bonded on the GORE ACUSEAL Vascular Graft?...4 How long does the heparin last?...4 How many International Units of heparin are on the surface of a GORE ACUSEAL Vascular Graft?...4 Clinical Practice Implantation Is the GORE ACUSEAL Vascular Graft similar to the GORE-TEX Stretch Vascular Graft? Do I have to tension the graft during implantation?...5 Are there special tunneling techniques for the GORE ACUSEAL Vascular Graft?...5 Are there special techniques when cutting the GORE ACUSEAL Vascular Graft?...5 Are there special techniques when sizing the GORE ACUSEAL Vascular Graft to the anastomosis?...5 What kind of suture can be used with the GORE ACUSEAL Vascular Graft?...6 Early Cannulation How early can the GORE ACUSEAL Vascular Graft be cannulated?...7 How early has the GORE ACUSEAL Vascular Graft been cannulated?...7 Are there special precautions when cannulating the GORE ACUSEAL Vascular Graft in the early postoperative period?...7 How long do you hold the cannulation site after the needle has been removed?...7 In which clinical situations can the greatest benefit be expected with the GORE ACUSEAL Vascular Graft?...7 Anticoagulation Do I have to change my patient s anticoagulation regimen?...8 Can I change my anticoagulation procedure while using the GORE ACUSEAL Vascular Graft?...8 What kind of anticoagulation does Gore recommend?...8 Can systemic heparin be reduced while using the GORE ACUSEAL Vascular Graft?...8 What is the effect of Protamine on the GORE ACUSEAL Vascular Graft?...8 Can a GORE ACUSEAL Vascular Graft be implanted in patients with existing heparin-induced thrombocytopaenia (HIT)?...8 What treatment protocol should I follow if a GORE ACUSEAL Vascular Graft patient develops HIT?...8 References...9 Commonly requested GORE-TEX Sutures reference table...6 Is there any difference in perioperative or postoperative bleeding?...6 Can the GORE ACUSEAL Vascular Graft be revised?...6 Does a thrombectomy procedure damage the heparin bonding?...6 What happens if the GORE ACUSEAL Vascular Graft is clamped does it damage the heparin surface of the graft?...6

GORE ACUSEAL Vascular Graft Properties What is the GORE ACUSEAL Vascular Graft? The GORE ACUSEAL Vascular Graft is a multi-layer vascular graft which includes an elastomer membrane between the inner and outer layers of expanded polytetrafluoroethylene (eptfe). The eptfe luminal surface of the GORE ACUSEAL Vascular Graft incorporates a proprietary end-point immobilized heparin technology referred to as CBAS Surface which imparts thromboresistant properties to the vascular graft. Tri-layer construction of a GORE ACUSEAL Vascular Graft Abluminal Layer: eptfe Graft Elastomeric Layer Luminal Layer: eptfe with CBAS Surface 500x magnification 100µ Low Bleed GORE ACUSEAL Vascular Graft vs Bleed Standard eptfe Graft Post cannulation of the luminal surface with a 16 gauge needle 2

Thromboresistance Evaluation of GORE ACUSEAL Vascular Graft in a Benchtop Canine Blood Flow Loop Model GORE ACUSEAL Vascular Graft without CBAS Surface GORE ACUSEAL Vascular Graft with CBAS Surface What is unique about the GORE ACUSEAL Vascular Graft? Low bleed barrier Elastomeric layer eptfe inner layer CBAS Surface on the blood flow surface Outer eptfe perivascular tissue contact surface Uniform structure throughout the length of the graft What are the benefits of the GORE ACUSEAL Vascular Graft? Hinders suture line bleeding Hinders hemodialysis cannulation needle bleeding May reduce risk of seroma formation May reduce risk of pseudoaneurysm Proven thromboresistance surface Kink resistance Are the microstructures of GORE-TEX Vascular Grafts and GORE ACUSEAL Vascular Grafts similar? The luminal eptfe layer of the GORE ACUSEAL Vascular Graft has the same microstructure as a GORE-TEX Vascular Graft. 3

CBAS Surface and Heparin Who is Carmeda AB? Carmeda AB, a Swedish company, invented the CBAS Surface, an end-point heparin bonding technology used on the GORE ACUSEAL Vascular Graft and other medical devices. In October 2005, Carmeda AB became a wholly owned subsidiary of W. L. Gore & Associates, Inc. Does Carmeda AB have a history of working with heparin technology? Carmeda AB is recognized as the world leader in heparin technology with a long history of pioneering research in this field since the company was founded in 1984. What kind of heparin is bonded on the GORE ACUSEAL Vascular Graft? CBAS Surface 2-heparin, a reduced molecular weight heparin of porcine origin and sourced in North America, is used in the construction of all GORE ACUSEAL Vascular Grafts. This CBAS Surface 2-heparin is a component specific for end-point attachment to medical devices. How long does the heparin last? In order to resist thrombus buildup, it is essential that heparin is present on the surface and retains its bioactive function. Graft explants from an in vivo canine model demonstrated the continued presence of heparin on the graft surface and showed sustained heparin bioactivity over a period of 12 weeks. 1 Riesenfeld has reported substantial bioactivity on Berlin Heart Ventricular Assist Device (which uses the same CBAS Surface technology used on the GORE ACUSEAL Vascular Graft) removed from a patient after 855 days. 2 Furthermore, human explants at approximately eight months, three years, four years and eight years post-implantation for peripheral arterial bypass have demonstrated heparin bioactivity above the level required for thromboresistance in a challenging blood contact model. How many International Units of heparin are on the surface of a GORE ACUSEAL Vascular Graft? Heparin activity in solution is typically measured in terms of International Units (IU). Surface bound heparin, on the other hand, is normally measured in terms of picomoles of antithrombin III (ATIII) uptake. A reasonable estimate of the number of IU on the graft surface can be obtained via theoretical calculations. The total amount of heparin bound to each graft is very low when compared to a common intraoperative dose of heparin. The typical amount of heparin present on a GORE ACUSEAL Vascular Graft (6 mm x 50 cm) is approximately 60 International Units (IU). This represents 1% of a common intraoperative dose of 5000 IU of heparin administered during vascular surgery. 4

Clinical Practice Implantation Is the GORE ACUSEAL Vascular Graft similar to the GORE-TEX Stretch Vascular Graft? Do I have to tension the graft during implantation? The GORE ACUSEAL Vascular Graft does not need to be pretensioned prior to implantation. While the graft affords a small amount of longitudinal extensibility, it should not be in a state of excessive tension when implanted. Scissors Clamp / Blade Are there special tunneling techniques for the GORE ACUSEAL Vascular Graft? Standard tunneling techniques can be used with the GORE ACUSEAL Vascular Graft. Create a tissue tunnel that closely approximates the outer graft diameter. The 6 mm GORE ACUSEAL Vascular Graft has an outer diameter of 8.8 mm. Are there special techniques when cutting the GORE ACUSEAL Vascular Graft? Always cut the GORE ACUSEAL Vascular Graft with a sharp surgical instrument. A different appearance is seen when cutting the GORE ACUSEAL Vascular Graft with scissors versus a clamp and blade. Sharp scissors create a smooth appearance to the wall of the vascular graft. A clamp and blade cut causes compression of the eptfe microstructure and retraction of the eptfe layers, creating a different appearance in the wall of the vascular graft. Either technique is acceptable. When suturing, be sure to pass the needle and thread through all three layers of the GORE ACUSEAL Vascular Graft. Are there special techniques when sizing the GORE ACUSEAL Vascular Graft to the anastomosis? Care must be taken when sizing the GORE ACUSEAL Vascular Graft to the arteriotomy or venotomy. The luminal diameter is 6 mm, the wall thickness is 1.4 mm and the outer diameter is 8.8 mm. Match the inner diameter of the graft wall with the outer perimeter of the opening of the vessel. 5

What kind of suture can be used with the GORE ACUSEAL Vascular Graft? Either GORE-TEX Suture (Table 1) or polypropylene suture can be used with the GORE ACUSEAL Vascular Graft. Commonly Requested GORE-TEX Sutures Table 1 Thread Size Needles Thread Length (cm) Catalogue Number CV-6 TTc-9 46 6J02 TTc-9 61 6K06 TTc-9 76 6M02 TTc-12 61 6K10 TTc-12 76 6M10 TTc-13 46 6J04 TTc-13 61 6K04 TTc-13 76 6M04 TTc-13 91 6N04 CV-7 TTc-9 46 7J02 TTc-9 61 7K02 TTc-9 76 7M02 CV-8 TTc-9 46 8J02 TTc-9 61 8K02 TTc-9 76 8M02 Is there any difference in perioperative or postoperative bleeding? The GORE ACUSEAL Vascular Graft is designed to provide heparin function at the graft surface; systemic anticoagulation remains unaffected. Because the GORE ACUSEAL Vascular Graft has an elastomeric middle layer, perioperative and postoperative bleeding is hindered. Can the GORE ACUSEAL Vascular Graft be revised? All standard revision procedures can be performed on the GORE ACUSEAL Vascular Graft, including lytic therapy and balloon thrombectomy. The heparin surface remains intact even after repeated in vitro pseudo-balloon thrombectomy procedures.* When applying clamps, care should be taken to avoid mechanical damage to, or disruption of, the graft. Use the appropriate atraumatic or guarded (for example, rubber shod) clamps. Avoid repeated, localized clamping or excessive clamping on any section of the graft. Does a thrombectomy procedure damage the heparin bonding? In vitro tests have shown that the heparin surface is still intact even after an inflated thrombectomy balloon was pulled through the graft three times.* What happens if the GORE ACUSEAL Vascular Graft is clamped does it damage the heparin surface of the graft? Graft clamping, according to recommended procedure, has no effect on the heparin surface or elastomeric layer. The heparin bonding is very stable and is not easily removed by mechanical methods. As with any prosthetic vascular graft, atraumatic or guarded clamps should be used and repeated, localized clamping of the same graft section should be avoided. * Data on file 6

Early Cannulation How early can the GORE ACUSEAL Vascular Graft be cannulated? The GORE ACUSEAL Vascular Graft can be cannulated within 24 hours after implantation. See the special considerations described below for optimal patient outcomes. How early has the GORE ACUSEAL Vascular Graft been cannulated? As of this publication, the earliest a GORE ACUSEAL Vascular Graft has been cannulated for hemodialysis is two hours post-implantation. This patient did not have a central venous catheter. By implanting the GORE ACUSEAL Vascular Graft and permitting early cannulation, the patient did not require a central venous catheter. Are there special precautions when cannulating the GORE ACUSEAL Vascular Graft in the early postoperative period? Yes. Adherence to aseptic technique is important. It is advised to wear sterile gloves since surgical incisions have not had sufficient time to heal. Certain sites have used the following practices for cannulation in the early postoperative period. 3 Local anesthesia Prevent graft movement prevented during cannulation Swift, clean puncture with a small (17 gauge) needle Reduced blood flow of 200 250 ml / min Administration of a lower dose of heparin if bleeding from incision sites How long do you hold the cannulation site after the needle has been removed? In the early postoperative period and beyond, it is recommended to hold digital pressure at the needle exit site for 10 15 minutes, as for any healed, conventional vascular graft. Not applying constant pressure for 10 15 minutes can cause blood to leak out of the cannulation site and into the subcutaneous tunnel, potentially causing a hematoma. In which clinical situations can the greatest benefit be expected with the GORE ACUSEAL Vascular Graft? Patients in need of hemodialysis who do not have a central venous catheter are the ideal candidates for a GORE ACUSEAL Vascular Graft. If the patient has a central venous catheter, the catheter can be removed sooner if the GORE ACUSEAL Vascular Graft is implanted instead of a non-early cannulation vascular graft. Patients who are prone to develop pseudoaneurysms in their vascular grafts or arteriovenous fistulas or patients who have experienced seroma formation with other vascular grafts can benefit from the GORE ACUSEAL Vascular Graft. 7

Anticoagulation Do I have to change my patient s anticoagulation regimen? It is not necessary to change the patient s anticoagulation regimen. The thromboresistant effect of the heparin on a GORE ACUSEAL Vascular Graft is limited to the device surface and does not have a systemic anticoagulant effect. 4 Can I change my anticoagulation procedure while using the GORE ACUSEAL Vascular Graft? The clinician should consider the need for intraoperative and / or postoperative anticoagulation therapy based on the pharmacological requirements and medical history of the patient. The presence of heparin on the GORE ACUSEAL Vascular Graft is not intended to serve as an alternative to the surgeon s chosen intraoperative or postoperative anticoagulation regimens. What kind of anticoagulation does Gore recommend? The clinician should determine the appropriate anticoagulation therapy based on the pharmacological requirements and medical history of the patient. The presence of heparin on the GORE ACUSEAL Vascular Graft is not intended to serve as an alternative to intraoperative or postoperative anticoagulation. Can systemic heparin be reduced while using the GORE ACUSEAL Vascular Graft? The presence of heparin on the GORE ACUSEAL Vascular Graft is not intended to serve as an alternative to intraoperative or postoperative anticoagulation. The thromboresistant effect of the heparin on a GORE ACUSEAL Vascular Graft is limited to the device surface and does not have a systemic anticoagulant effect. What is the effect of Protamine on the GORE ACUSEAL Vascular Graft? Although Protamine reverses the anticoagulant activity of heparin, its effect is transitory. Protamine can only remain bound to heparin when it is present in sustained excess quantities. Since Protamine is rapidly removed from the circulation, any effect is short-lived. Can a GORE ACUSEAL Vascular Graft be implanted in patients with existing heparin-induced thrombocytopaenia (HIT)? The GORE ACUSEAL Vascular Graft is contraindicated for use in patients with known hypersensitivity to heparin, including those patients who have had a previous or existing incidence of HIT type II. What treatment protocol should I follow if a GORE ACUSEAL Vascular Graft patient develops HIT? The incidence of HIT type II is extremely low in vascular bypass patients receiving systemic heparin over a period of several days. If HIT type II is diagnosed, established procedures for the treatment of this condition, including immediate cessation of systemic heparin administration, should be followed. If symptoms persist, alternative procedures can be considered at the discretion of the attending physician. 8

References 1. Begovac PC, Thomson RC, Fisher JL, Hughson A, Gällhagen A. Improvements in GORE-TEX Vascular Graft performance by Carmeda bioactive surface heparin immobilization. European Journal of Vascular and Endovascular Surgery 2003;25(5):432-437. 2. Riesenfeld J, Ries D, Hetzer R. Analysis of the heparin coating of an EXCOR Ventricular Assist Device after 855 days in a patient. Abstract presented at the 32nd Society for Biomaterials Annual Meeting. April 18-21, 2007. Chicago, IL. Abstract 180. 3. Hudson P. Early cannulation of vascular access sites for dialysis. Dialysis & Transplantation 1996;8:523-526. 4. Heyligers JMM, Lisman T, Verhagen HJM, Weeterings C, de Groot PhG, Moll FL. A heparin-bonded vascular graft generates no systemic effect on markers of haemostasis activation or detectable HIT-inducing antibodies in humans. In: Heyligers JMM, ed. Novel Strategies To Improve the Patency of Vascular Prostheses. 2006;7:95-108. 9

W. L. Gore & Associates, Inc. Flagstaff, AZ 86004 +65.67332882 (Asia Pacific) 00800.6334.4673 (Europe) 800.437.8181 (United States) 928.779.2771 (United States) goremedical.com Products listed may not be available in all markets. GORE, GORE-TEX, ACUSEAL, PERFORMANCE THROUGH INNOVATION, PROPATEN, and designs are trademarks of W. L. Gore & Associates. CARMEDA and CBAS are trademarks of Carmeda AB, a wholly owned subsidiary of W. L. Gore & Associates, Inc. 2011, 2013 W. L. Gore & Associates, Inc. AQ0107-EU3 MAY 2013